Mammoth Biosciences
Wei-Cheng (Winston) Chang is a Scientist at Mammoth Biosciences since May 2022, previously serving as a Senior Research Associate at Genentech from October 2020 to May 2022 and at SanBio, Inc. from May 2019 to September 2020. Wei-Cheng earned a Doctor of Philosophy in Cell/Cellular and Molecular Biology from the University of California, Berkeley, where studies were conducted from 2012 to 2018. Additionally, Wei-Cheng holds a Master's degree in Neuroscience from National Yang Ming University, completed between 2005 and 2008.
This person is not in any teams
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.